B. Riley Reaffirms Buy Rating for Iovance Biotherapeutics (IOVA)

B. Riley reissued their buy rating on shares of Iovance Biotherapeutics (NASDAQ:IOVA) in a research report report published on Wednesday morning. The firm currently has a $18.00 target price on the biotechnology company’s stock.

Several other equities research analysts have also commented on the company. HC Wainwright set a $16.00 price target on Iovance Biotherapeutics and gave the stock a buy rating in a research note on Thursday. Oppenheimer set a $13.00 price target on Iovance Biotherapeutics and gave the stock a buy rating in a research note on Thursday. BidaskClub lowered Iovance Biotherapeutics from a strong-buy rating to a buy rating in a research note on Wednesday, December 6th. Zacks Investment Research lowered Iovance Biotherapeutics from a buy rating to a hold rating in a research note on Friday, November 3rd. Finally, Jefferies Group restated a buy rating on shares of Iovance Biotherapeutics in a research note on Sunday, October 29th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Iovance Biotherapeutics has a consensus rating of Buy and a consensus price target of $14.53.

Iovance Biotherapeutics (IOVA) opened at $9.05 on Wednesday. Iovance Biotherapeutics has a 12 month low of $4.45 and a 12 month high of $9.54.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.01). sell-side analysts forecast that Iovance Biotherapeutics will post -1.37 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Orbimed Advisors LLC boosted its position in shares of Iovance Biotherapeutics by 89.9% in the third quarter. Orbimed Advisors LLC now owns 6,425,626 shares of the biotechnology company’s stock worth $49,799,000 after buying an additional 3,042,726 shares during the period. Franklin Resources Inc. purchased a new stake in shares of Iovance Biotherapeutics in the second quarter worth about $37,844,000. Perceptive Advisors LLC boosted its position in shares of Iovance Biotherapeutics by 8.3% in the third quarter. Perceptive Advisors LLC now owns 4,726,114 shares of the biotechnology company’s stock worth $36,627,000 after buying an additional 363,000 shares during the period. FMR LLC purchased a new stake in shares of Iovance Biotherapeutics in the second quarter worth about $20,833,000. Finally, Victory Capital Management Inc. boosted its position in shares of Iovance Biotherapeutics by 2.0% in the third quarter. Victory Capital Management Inc. now owns 2,638,323 shares of the biotechnology company’s stock worth $20,447,000 after buying an additional 51,450 shares during the period. 75.93% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “B. Riley Reaffirms Buy Rating for Iovance Biotherapeutics (IOVA)” was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.thelincolnianonline.com/2017/12/17/b-riley-reaffirms-buy-rating-for-iovance-biotherapeutics-iova.html.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Analyst Recommendations for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply